Evidence map›Paper›PMID 18278977›Full record

ReviewCNS drugs2008

Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

Johnny Graham, David Coghill

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in CNS drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04316832 (A Randomized-Controlled Trial), which is not on this map. Cited by 79 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04316832 nacompletednot on this mapstarted 2020, after this paper: background citation

A Randomized-Controlled Trial: the Effectiveness of a Single-session of Mindfulness Based Cognitive Training on CVC and Core Symptoms in Children and Adolescents With ADHD

TypeinterventionalSponsorBabes-Bolyai UniversityRan2020 to 2021Enrolled70ConditionsADHDArmsMindfulness based cognitive training, Control exercise
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Johnny GrahamChild and Adolescent Psychiatry, University of Dundee, Section of Psychiatry, Division of Pathology and Neuroscience, Ninewells Hospital, Dundee, Scotland. J.G.I.Graham@dundee.ac.uk
David Coghill

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medication for the treatment of attention-deficit hyperactivity disorder (ADHD) is in widespread use globally. There is considerable data suggesting that overall, the adverse effect burden from this use is dose dependent and is in the mild to moderate category, but few comprehensive reviews exist of the epidemiology of adverse effects alone. This review provides a general and systems-specific summary of the scientific literature regarding adverse effect data for the drugs in general use for the treatment of ADHD. Although several areas lack definitive data, current evidence suggests that, for the majority of those treated for ADHD, the medications currently available pose little in the way of risk of significant harm. Epidemiological data suggest a low incidence of serious adverse effects, whilst the less serious adverse effects, such as insomnia and anorexia, are relatively common. Also, some specific areas of study suggest lower risks of harm than previously thought, e.g. tic disorders and seizures. However, pre-existing conditions and other interindividual differences may raise the risk of harmful adverse effects, which adds emphasis to the need for careful pretreatment assessment and monitoring. Potential but unlikely long-term treatment effects need to be investigated as carefully as possible, particularly with regard to cardiac sequelae and carcinogenesis. There are both overlaps and differences between the adverse effects of stimulants and nonstimulants, such as atomoxetine. For example, the latter shares the stimulant group's potential for changing cardiovascular parameters, but may not cause insomnia.

Indexed as

Antidepressive AgentsAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityCardiovascular DiseasesCentral Nervous System StimulantsClinical Trials as TopicGrowth DisordersHumansMental DisordersNervous System DiseasesPropylaminesAntidepressive AgentsAtomoxetine HydrochlorideCentral Nervous System StimulantsPropylamines

Identifiers

PMID18278977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.